

(54) **METHODS FOR DETECTING
PRE-DIABETES AND DIABETES USING
DIFFERENTIAL PROTEIN GLYCOSYLATION**

(75) Inventors: **Srinivasa R. Nagalla**, Hillsboro, OR
(US); **Charles T. Roberts**, Portland, OR
(US)

(73) Assignee: **DiabetOmics, LLC**, Beaverton, OR
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/777,955**

(22) Filed: **May 11, 2010**

(65) **Prior Publication Data**

US 2010/0285498 A1 Nov. 11, 2010

Related U.S. Application Data

(60) Provisional application No. 61/177,130, filed on May
11, 2009.

(51) **Int. Cl.**
G01N 33/53 (2006.01)

(52) **U.S. Cl.** **435/7.1; 436/518**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,168,146 A 9/1979 Grubb et al.
4,246,339 A 1/1981 Cole et al.
4,275,149 A 6/1981 Litman et al.
4,277,560 A 7/1981 Gray et al.
4,313,734 A 2/1982 Leuvinger
4,366,241 A 12/1982 Tom et al.
4,371,374 A 2/1983 Cerami et al.
4,373,932 A 2/1983 Gribnau et al.
4,433,304 A 3/1984 Zuk et al.
4,496,654 A 1/1985 Katz et al.
4,632,901 A 12/1986 Valkirs et al.
4,703,017 A 10/1987 Campbell et al.
4,740,468 A 4/1988 Weng et al.
4,743,560 A 5/1988 Campbell et al.
4,770,853 A 9/1988 Bernstein
4,775,636 A 10/1988 Moeremans et al.
4,806,311 A 2/1989 Greenquist
4,806,312 A 2/1989 Greenquist
4,812,293 A 3/1989 McLaurin et al.
4,855,240 A 8/1989 Rosenstein et al.
4,857,453 A 8/1989 Ullman et al.
4,861,711 A 8/1989 Friesen et al.
4,920,046 A 4/1990 McFarland et al.
4,943,522 A 7/1990 Fisinger et al.
4,945,042 A 7/1990 Geiger et al.
4,954,452 A 9/1990 Yost et al.
5,001,049 A 3/1991 Klein et al.
5,073,484 A 12/1991 Swanson et al.
5,075,078 A 12/1991 Osikowicz et al.
5,120,643 A 6/1992 Ching et al.
5,126,241 A 6/1992 Schenk
5,229,073 A 7/1993 Luo et al.
5,279,935 A 1/1994 Nycz

5,424,193 A 6/1995 Pronovost et al.
5,451,504 A 9/1995 Fitzpatrick et al.
5,451,507 A 9/1995 Skold et al.
5,591,645 A 1/1997 Rosenstein
5,712,172 A 1/1998 Huang et al.
5,798,273 A 8/1998 Shuler et al.
6,001,658 A 12/1999 Fredrickson
6,258,548 B1 7/2001 Buck
6,283,761 B1 9/2001 Joao
6,368,876 B1 4/2002 Huang et al.
6,555,390 B2 4/2003 Chandler
6,656,744 B2 12/2003 Pronovost et al.
6,699,722 B2 3/2004 Bauer et al.
6,716,592 B1 4/2004 Rademacher et al.
7,183,118 B2 2/2007 Aebersold et al.
2003/0049857 A1 3/2003 Chan
2004/0241876 A1 12/2004 Fannes

FOREIGN PATENT DOCUMENTS

EP 0296724 A2 12/1988
EP 0299428 A2 1/1989
EP 0810436 A1 12/1997
WO 88/08534 A1 11/1988
WO 92/12428 A1 7/1992
WO 94/01775 A1 1/1994
WO 95/16207 A1 6/1995
WO 97/06439 A1 2/1997
WO 98/36278 A1 8/1998
WO 01/40796 A2 6/2001
WO 2007/123951 A2 11/2007
WO 2008/030546 A2 3/2008
WO 2008/055242 A2 5/2008
WO 2009/028880 A2 3/2009

OTHER PUBLICATIONS

Poland, Dennis C.W. et al., "Increased alpha 3-Fucosylation of alpha
1-acid Glycoprotein in Type I Diabetic Patients is Related to Vascular
Function," Glycoconjugate Journal, 2001, vol. 18, pp. 261-268.
Carlsson, Jenny et al., "Detection of Global Glycosylation Changes
of Serum Proteins in Type I Diabetes Using a Lectin Panel and
Multivariate Data Analysis," Talanta, 2008, vol. 76, pp. 333-337.
Duse, Maria G. et al., "Enhanced O-GlcNAc Protein Modification is
Associated with Insulin Resistance in GLUT1-Overexpressing
Muscles," Am J Physiol Endocrinol Metab, 2002, vol. 283, pp. E241-
E250.
Higai, Koji et al., "Altered Glycosylation of alpha1-acid
Glycoprotein in Patients with Inflammation and Diabetes Mellitus,"
Clinica Chimica Acta, 2003, vol. 329, pp. 117-125.
Wang, Linjie et al., "Concanavalin A-captured Glycoproteins in
Healthy Human Urine," Molecular & Cellular Proteomics 5.3, 2006,
pp. 560-562.

(Continued)

Primary Examiner — Jacob Cheu

(74) *Attorney, Agent, or Firm* — Schwabe, Williamson &
Wyatt

(57) **ABSTRACT**

Methods for identifying individuals who are not yet diabetic
(pre-diabetic), but who are at significant risk of developing
diabetes, such as type 2 diabetes, are disclosed herein. Meth-
ods are also provided for the identification of diabetic sub-
jects. Also disclosed are methods for identifying individuals
with diabetic complications. The methods include the identi-
fication of an overall glycosylation profile of proteins in a
biological fluid, such as saliva, urine, or serum. In some
examples, the methods include determining the amount of
one or more protein in a biological fluid or determining the
glycosylation pattern of one or more proteins in a biological
fluid.

29 Claims, 7 Drawing Sheets